Generated July 14, 2026 at 8:32 PM ET
· Covers July 14 trading day
· 10 of 172 ready 8-Ks selected
· AI-assisted overview
NextCure (NXTC) announced a reverse merger with Avere Therapeutics, with Avere holders receiving ~98% of the combined company and a concurrent $320M PIPE. Ligand completed its acquisition of XOMA Royalty (XOMA) for $39.00 per share plus CVRs, and National Storage Affiliates Trust (NSA) shareholders approved its acquisition by Public Storage, with closing expected July 22. CleanSpark (CLSK) signed a 20-year, $6.6B lease for a 175 MW Georgia data center with a high-grade tenant. Pentair (PNR) reported preliminary Q2 sales of $930M, down 17% versus prior guidance, and cut its full-year EPS guidance. Genprex (GNPX) filed a 1:22 reverse stock split to address a Nasdaq bid price deficiency and faces delisting risk.
BUSE
FIRST BUSEY CORP /NV/
leadership
positive
materiality 0.65
July 14, 2026, 5:06 PM ET
Busey CEO Van Dukeman extends contract through July 2029; declares $0.26 dividend
- CEO Van Dukeman's term extended to July 1, 2029; base salary, bonus, and equity unchanged.
- One-time retention RSU grant of $2,067,749.88 vesting on July 1, 2029, subject to continued employment.
- Quarterly dividend of $0.26 per common share declared, payable July 31, 2026 to holders of record July 24, 2026.
M&A
negative
materiality 1.00
July 14, 2026, 7:00 AM ET
NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE
- NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.
- Concurrent $320M private placement from institutional investors into Avere; condition of at least $150M proceeds at close.
- NextCure to reduce workforce by substantial majority; expects ~$1.9M one-time charges in Q3 2026.
M&A
positive
materiality 1.00
July 14, 2026, 9:10 AM ET
Ligand completes acquisition of XOMA Royalty for $39.00/share plus CVRs
- Stockholders received $39.00 cash per share plus one CVR per share entitling holder to 75% of net proceeds from certain pending litigation.
- Merger approved by stockholders with 15.9M votes for, 98K against; closing occurred July 14, 2026.
- XOMA Royalty common stock delisted from Nasdaq; loan agreement with Blue Owl Capital terminated.
NSA
National Storage Affiliates Trust
M&A
positive
materiality 0.90
July 14, 2026, 4:19 PM ET
NSA shareholders approve acquisition by Public Storage; closing expected July 22
- 99.9% of votes cast in favor of the merger, representing >84% of outstanding common shares.
- Transaction expected to close on or about July 22, 2026, subject to customary conditions.
- No further equity holder approval required; OP unit holders previously approved.
RNA
Atrium Therapeutics, Inc.
regulatory
positive
materiality 0.65
July 14, 2026, 5:14 PM ET
Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start
- FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.
- Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.
- Initial proof-of-concept data anticipated in second half of 2027.
RMAX
RE/MAX Holdings, Inc.
regulatory
positive
materiality 0.60
July 14, 2026, 8:00 AM ET
DOJ grants early termination of HSR waiting period for RE/MAX-Real merger
- On July 13, 2026, the U.S. Department of Justice granted early termination of the HSR Act waiting period for the proposed merger with Real Brokerage.
- HSR filings were initially made May 13, 2026, withdrawn and refiled June 12/15, 2026, per 16 C.F.R. § 803.12.
- Closing remains subject to shareholder approvals of both RE/MAX Holdings and Real, plus other customary conditions.
earnings
negative
materiality 0.85
July 14, 2026, 5:20 PM ET
Pentair prelim Q2 sales $930M (-17% vs guide), cuts FY EPS guide to $3.90-$4.10 from $4.83-$4.93
- Preliminary Q2 sales ~$930M, down 17% vs prior guide of up ~1%; GAAP EPS ~$0.80 vs guide $1.39-$1.42; adjusted EPS ~$1.12 vs guide $1.47-$1.50.
- Pool channel destocking negatively impacted Q2 sales by ~$170M and segment income by ~$105M; IEEPA refunds contributed ~$35M.
- Full-year 2026 guidance revised: sales down 4-7% (prior up 2-4%), GAAP EPS $3.90-$4.10 (prior $4.83-$4.93), adjusted EPS $4.60-$4.80 (prior $5.30-$5.40).
other material
positive
materiality 0.90
July 14, 2026, 6:05 AM ET
CleanSpark signs 20-year, $6.6B lease with high-grade tech tenant for 175 MW Georgia data center
- Triple-net lease with annual escalators; initial term 20 years, two 5-year extensions; total potential value $11.6B.
- Tenant (confidential, high-investment-grade) will lease 175 MW critical IT load at Sandersville, GA; deliveries expected Q4 2027.
- Expected cumulative NOI contribution margin nearly 100%, average annual NOI ~$330M; landlord project costs $10-12M per MW.
BNET
BION ENVIRONMENTAL TECHNOLOGIES INC
litigation
positive
materiality 0.75
July 14, 2026, 1:03 PM ET
Bion settles Fair Oaks construction litigation; issues $1.77M convertible note to Hamstra
- Settlement with Hamstra Builders dismisses all mechanics liens and litigation related to Fair Oaks Ammonia Recovery System construction.
- Bion issues $1,774,512.72 convertible promissory note to Hamstra: 10% interest, maturity Dec 31, 2026, cash payment of $653,915 at future financing, balance convertible at that financing price.
- All holders of Bion's Secured Convertible Notes and May 2024 Notes (maturity June 30, 2026) extend maturity to Dec 31, 2026; Bion Loan Group note extended to Jan 31, 2027.
other material
negative
materiality 0.85
July 14, 2026, 9:23 AM ET
Genprex files 1:22 reverse stock split to address Nasdaq bid price deficiency; faces delisting risk
- Reverse stock split at 1:22 ratio effective July 16, 2026; shares outstanding to reduce from ~11.1M to ~505K.
- Received Nasdaq delisting notice on June 10, 2026 for failing to maintain $1.00 bid price; requested hearing.
- Acclaim-1 Phase 2a enrolling; Acclaim-3 Phase 2 expansion enrolling, interim analysis expected H1 2027.